Kestra Medical Technologies, Ltd. Increase (Decrease) in Accounts Receivable
Kestra Medical Technologies, Ltd. (KMTS) reported Increase (Decrease) in Accounts Receivable of $48.00 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-09-14
- Kestra Medical Technologies, Ltd. increase (decrease) in accounts receivable for the quarter ending 2026-07-31 was $48.00K, a 97.30% decline year-over-year.
- Kestra Medical Technologies, Ltd. increase (decrease) in accounts receivable for the quarter ending 2026-04-30 was $2.91M, a 202.49% increase year-over-year.
- Kestra Medical Technologies, Ltd. increase (decrease) in accounts receivable for the quarter ending 2026-01-31 was $2.66M, a 20.42% decline year-over-year.
- Kestra Medical Technologies, Ltd. increase (decrease) in accounts receivable for the quarter ending 2025-10-31 was $1.71M, a 7.91% increase year-over-year.
- Kestra Medical Technologies, Ltd. increase (decrease) in accounts receivable for fiscal 2026 was $9.06M, a 3.18% increase from fiscal 2025.
- Kestra Medical Technologies, Ltd. increase (decrease) in accounts receivable for fiscal 2025 was $8.78M, a 251.36% increase from fiscal 2024.
- Kestra Medical Technologies, Ltd. increase (decrease) in accounts receivable for fiscal 2024 was $2.50M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-07-31 | $48.00K 10-Q · filed 2026-09-14 | $2.96M derived: sum of 2 quarters · filed 2026-09-14 | $5.62M derived: sum of 3 quarters · filed 2026-09-14 | $7.33M derived: sum of 4 quarters · filed 2026-09-14 |
| 2026-04-30 | $2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-14 | $5.57M derived: sum of 2 quarters · filed 2026-07-14 | $7.28M derived: sum of 3 quarters · filed 2026-07-14 | $9.06M 10-K · filed 2026-07-14 |
| 2026-01-31 | $2.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-17 | $4.37M derived: sum of 2 quarters · filed 2026-03-17 | $6.14M 10-Q · filed 2026-03-17 | $7.11M derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-10-31 | $1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-11 | $3.48M 10-Q · filed 2025-12-11 | $4.45M derived: sum of 3 quarters · filed 2026-09-14 | $7.79M derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-07-31 | $1.78M 10-Q · filed 2026-09-14 | $2.74M derived: sum of 2 quarters · filed 2026-09-14 | $6.08M derived: sum of 3 quarters · filed 2026-09-14 | $7.66M derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-04-30 | $963.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-14 | $4.31M derived: sum of 2 quarters · filed 2026-07-14 | $5.89M derived: sum of 3 quarters · filed 2026-07-14 | $8.78M 10-K · filed 2026-07-14 |
| 2025-01-31 | $3.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-17 | $4.92M derived: sum of 2 quarters · filed 2026-03-17 | $7.81M 10-Q · filed 2026-03-17 | |
| 2024-10-31 | $1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-11 | $4.47M 10-Q · filed 2025-12-11 | ||
| 2024-07-31 | $2.89M 10-Q · filed 2025-09-12 | |||
| 2024-04-30 | $2.50M 10-K · filed 2025-07-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| NovoCure Ltd (NVCR) | $1.886B | -11.87 | |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |